B1Q Stock Chart & Stats
€2.09
€0.00(0.00%)
At close: 4:00 PM EST
€2.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.37 - €4.13
Previous CloseN/A
Volume0.00
Average Volume (3M)203.00
Market Cap
€153.77M
Enterprise Value€63.07
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€934.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding41,943,280
10 Day Avg. Volume609
30 Day Avg. Volume203
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.67Price Target Upside1558.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€12.18M
Bulls Say, Bears Say
Bulls Say
KETAFREE Regulatory & Manufacturing ProgressPreliminary FDA bioequivalence with only minor items plus VAI reclassification and a 1M‑unit batch BFS process gives NRX durable manufacturing scale and a first‑mover U.S. preservative‑free ketamine position. This materially lowers supply constraints and supports launch inventory and commercial execution if approval is granted.
NRX‑100 NDA Backed By Extensive RWEA dossier combining controlled trials and >65,000‑patient real‑world evidence can materially shorten regulatory friction and broaden label potential (including suicidality). That structural evidentiary base improves approval odds, payer discussions, and the product's commercial addressability versus typical small biopharma filings.
Pipeline Breadth & Strategic Research LinksThe Geneuro asset acquisition plus a defense‑focused subsidiary (NRx Defense Systems) expands therapeutic modalities and scientific depth, diversifying clinical risk across CNS and immunologic targets. This increases option value, potential non‑dilutive funding paths and long‑term R&D flexibility beyond a single molecule bet.
Bears Say
Persistent Cash Burn & Negative EquitySustained multi‑million dollar operating and free cash outflows and an accumulated deficit constrain strategic optionality. Negative equity signals recurring losses and limits borrowing capacity, meaning the company will likely need external funding until revenue scales or costs are meaningfully reduced, raising execution risk.
Capital Dependence And Dilution RiskOngoing reliance on ATM sales and public offerings to fund operations creates recurring dilution risk and governance pressure. This funding model can force timing‑sensitive financing, constrain long‑term planning, and increase the probability of shareholder dilution if clinical or regulatory milestones slip.
Commercial Channel & Market Execution RiskNeeding to develop both traditional wholesaler/hospital pathways and a clinic‑focused channel to displace compounding pharmacies is a structural commercial challenge. It requires payer engagement, distributor relationships, and sales infrastructure, any shortfall of which would materially delay revenue scaling and increase commercial costs.
NRX Pharmaceuticals News
B1Q FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was €1.37 and its highest was €4.13 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is €153.77M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of €0.183 by -€0.218.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.1.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 41,943,280 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -€0.035 in its last earnings report, missing expectations of €0.183. Following the earnings report the stock price went up 7.895%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:B1Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
B1Q Stock 12 Month Forecast
Average Price Target
€34.67
▲(1558.99% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―